Taisho Pharmaceutical Co., Ltd.
Saitama, Japan
Nagahiro Ochiai has been uncovering new molecular mechanisms in bone metabolism through multi-omics approaches. After earning his degree from the Biochemistry Laboratory at Tokushima University in 2007, he joined Taisho Pharmaceutical in 2008. In 2017, he was seconded to the Genome Medical Research Center at Saitama Medical University, where he conducted pivotal research on osteoclasts. Since 2022, he has been researching at the Department of Musculoskeletal Regenerative Medicine, Osaka University Graduate School of Medicine, focusing on the response to mechanical loading in glucocorticoid-induced osteoporosis.
Monday, November 18, 2024
9:15 AM – 9:30 AM Eastern Time
No financial relationships with ineligible companies to disclose